Mon, Mar 3, 9:16 PM (55 days ago)
**Pliant Therapeutics, Inc. (PLRX) 2024 10-K Summary:** Pliant Therapeutics reported a net loss of $210.3 million for the fiscal year ended December 31, 2024, increasing from $161.3 million in 2023, with an accumulated deficit of $710.1 million. The company focuses on developing therapies for fibrosis, with its lead candidate, bexotegrast, being an oral small molecule aimed at treating idiopathic pulmonary fibrosis (IPF). The BEACON-IPF Phase 2b trial was recently discontinued due to safety concerns, although preliminary efficacy was noted. The firm is also advancing PLN-101095 for solid tumors resistant to immune checkpoint inhibitors, with preliminary data expected in Q1 2025. The company faces significant risks, including reliance on third-party manufacturers and potential regulatory hurdles. Pliant's cash reserves of approximately $357.2 million are projected to sustain operations for the next 12 months. Future growth depends on successful clinical trials and strategic partnerships. The company has not declared dividends and intends to reinvest earnings into its development programs. Market volatility and regulatory changes pose additional challenges, impacting stock performance and operational stability.